← Eichor
Study identifier: NCT04022109 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach

Condition: Gastric Cancer · Atrophic Gastritis · Gastric Dysplasia  ·  Sponsor: University of Latvia

PhaseN/A
Planned participants5000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The study is aimed to determine the potential of volatile marker testing for gastric cancer screening. The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.

This description comes directly from the study's public registry record.

Talk to the study team

Marcis Leja, MD, PhD  ·  +37129497500  ·  marcis.leja@lu.lv

Daiga Santare, MD, PhD  ·  +37129221107  ·  daiga.santare@lu.lv

Always discuss trial participation with your own doctor first.

Locations (5)

A.C.Camargo Cancer CenterSão Paulo, BrazilRecruiting
Pontificia Universidad Catolica de ChileSantiago, ChileNot Yet Recruiting
Centro Javeriano de Oncología, San Ignacio University HospitalBogotá, ColombiaNot Yet Recruiting
Institute of Clinical and Preventive Medicine, University of LatviaRiga, LatviaRecruiting
National Cancer Institute of UkraineKiev, UkraineRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04022109